focus -WSS

focus

author：entertainment 2025-09-02 11:47:31 - browse：7385

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Key House panel plots a new health care package

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Sanofi seeks simpler, safer CRISPR sickle cell cure

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Headspace, Meta partner to launch VR meditation app for Quest

Key House panel plots a new health care package

Wikipedia

focus

leisure time

Moonlake's readout produced a cash windfall. Risks remain

RSV shot was 90% effective at preventing hospitalizations in kids

Jerome Adams on the need for new antivirals for Covid

NEJM study link tiny plastics in blood vessels to heart problems

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

State Dept. review finds Biden bears some blame for Afghanistan failures

How dance can help nurses traumatized by Covid

United colonoscopy coverage change 'may cost lives,' doctors say

NEJM study link tiny plastics in blood vessels to heart problems

focus

Medicare to cover more brain scans for Alzheimer’s patients

Medicare has a new plan to address drug shortages

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

First medicine developed to treat MASH expected to be approved soon

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

At Orexo, a ‘turning point’ for everything but digital health

Wikipedia

focus

hotspot

hotspot